臨床的に適用可能な統合的分子分類
Farshad Nassiri1,2,3, Jeff Liu1,3, Vikas Patil1,3
1MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Nature
|August 26, 2021
まとめ
最も一般的な脳腫瘍である 髄膜腫には4つの分子群が 定義されています これらのグループは 患者の治療結果を より良く予測し 異なる腫瘍生物学を明らかにし この一般的な頭蓋内腫瘍に対する 新しい治療法を導き出します
科学分野:
- 神経腫瘍学
- ゲノミクス
- プロテオミクス
背景:
- 髄膜腫は成人における最も一般的な一次性頭蓋内腫瘍である.
- 現在の治療は手術によるもので 有効な治療法はありません
- 既存の分類システムは 髄膜腫の行動を完全に予測したり 治療を指導したりできません
研究 の 目的:
- 臨床結果を正確に予測できる 髄膜腫の分子分類を開発する.
- 異なる生物学的亜型を識別する
- 髄膜腫の新たな治療標的を 発見するためです
主な方法:
- DNA複製数の偏差,点変異,メチル化,mRNAの豊富さの統合分析
- 免疫ヒストケミストリーを含むプロテオゲノム特性
- 単細胞RNAのシーケンス
主要な成果:
- 髄膜腫の4つのコンセンサス分子群が特定されました.
- これらの分子群は,既存のスキームと比較して,臨床結果の優れた予測を示した.
- 異なる生物学的プロファイル (免疫性,良性NF2野生型,超代謝性,増殖性) が各グループに関連した.
- グループ固有のタンパク質ターゲットが特定され,検証された.
結論:
- 新しい分子分類は 髄膜腫の行動を理解するための より正確な枠組みを提供します
- 異なる分子および生物学的特徴が潜在的治療戦略に情報を与えます.
- この分類は,髄膜腫の治療のためのパーソナライズド医療のアプローチを進めている.
関連する概念動画
01:25Drug Classes and Categories
3.1K
Drugs can be classified according to their chemical composition or their intended therapeutic application. For instance, anti-infective agents that possess the ability to eliminate pathogens or suppress their growth and reproduction can be grouped based on the organisms they target or their chemical structure. Furthermore, drugs can be divided into prescription, nonprescription, or controlled substances. Prescription medications, such as antibiotics, require oversight from a licensed healthcare...
3.1K
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
4.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.2K
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230
01:16Therapeutic Drug Monitoring: Overview and Classification
642
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
642
01:23Modified-Release Drug Delivery Systems: Classification
315
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
315